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Down syndrome (DS), caused by trisomy of whole or part of chromosome 21 is the
most common mental impairment. All people with DS suffer from cognitive decline and
develop Alzheimer’s disease (AD) by the age of 40. The appearance of enlarged early
endosomes, followed by Amyloid βpeptide deposition, the appearance of tau-containing
neurofibrillary tangles and basal forebrain cholinergic neuron (BFCN) degeneration are the
neuropathological characteristics of this disease. In this review we will examine the role of
metal ion dyshomeostasis and the genes which may be involved in these processes, and
relate these back to the manifestation of age-dependent cognitive decline in DS.
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INTRODUCTION
This review will discuss the role of intrinsic metals in cogni-
tive decline in people with Down syndrome (DS). DS, caused
by trisomy of whole or part of human chromosome 21 is the
most common mental impairment with an incidence of about
1 in 700 live births (Epstein, 1995). Characteristics of DS indi-
viduals have been described such as stunted growth, mental
impairment, congenital disorders of multi-organ systems such
as the heart, haematological, musculoskeletal, thyroid, gastroin-
testinal, dental, nervous and immune systems, and having a
higher incidence of diabetes and age-associated diabetes (Burch
and Milunsky, 1969; Peiris et al., 2012). Life expectancy of
people with DS has increased from 12 years in the 1940s to
60 years at the present time, largely due to enhanced medi-
cal and social care (Contestabile et al., 2010). Because of the
increased longevity, it has become evident that by the age of
40 (Mann et al., 1990), all individuals with DS have the cogni-
tive decline and the neuropathology seen in Alzheimer’s disease
(AD).
AD is the most common form of dementia. It was first
described by a German psychiatrist and neuropathologist named
Alois Alzheimer in 1906 (Alzheimer et al., 1995). One of the
earlier symptoms is short term memory loss. As the disease
progresses long-term memory loss, confusion and mood swing
occur. Sporadic AD and DS share similar neuropathological fea-
tures (Mann, 1988), these include the enlargement of early endo-
somes in certain neurons, deposition of Aβ plaques, the presence
of tau-containing neurofibrillary tangles and the degeneration
of basal forebrain cholinergic neuron (BFCN). The pattern of
pathology is similar but the symptoms appear earlier in individ-
uals with DS (Ikeda et al., 1989). In DS, enlarged endosomes
in neurons are seen as early as 28 weeks of gestation (Cataldo
et al., 2000). The presence of enlarged endosomes precedes Aβ
peptide deposition which appears at around 12 years of age in
the form of diffuse plaques, followed by mature Aβ plaques
when the individuals are in their 30’s (Lemere et al., 1996). In
a review of the literature, it was reported that most studies have
found that tau-containing neurofibrillary tangles occur in the
BFCN along with neuronal degeneration, gliosis and dementia
at ages of between 35 to 45 years (Wilcock and Griffin, 2013).
An immunohistochemical study of the brain tissues from post-
mortem DS individuals showed that in earlier years of life (37–38)
brain neuron loss was present and this progressed with age (over
50s) with abundant, mature amyloid deposits. Taken together,
these observations suggest that in DS there is an accelerated
progression occurring through the different stages of AD-like
neuropathology.
There are 127 known genes, 98 predicted genes and 59 pseudo
genes located on chromosome 21 (Hattori et al., 2000). It is
putatively thought that having an extra copy of one or more of
these genes could be responsible for the manifestation of AD-
like neuropathology and cognitive decline in DS. Some genes of
interest are: Amyloid precursor protein (APP), Down syndrome
candidate region 1 (DSCR1), Intersectin 1(ITSN1), Superoxide
dismutase 1(SOD1), Beta-site APP-cleaving enzyme 2 (βsecretase
or BACE 2), S100 calcium binding protein β(S100β).
In the next section, how these genes may be involved in
cognitive decline of DS will be discussed.
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GENES POTENTIALLY INVOLVED IN COGNITIVE DECLINE
OF DS
AMYLOID PRECURSOR PROTEIN (APP)
Studies have suggested that over-expression of the APP is the
key element for the manifestation of AD in DS (Schupf and
Sergievsky, 2002). A case study where an individual had partial
trisomy 21 that did not include an extra copy of the APP gene
confirmed this concept (Prasher et al., 1998). This individual
showed some characteristics of DS but did not suffer from AD
and the associated cognitive decline.
Amyloid peptides (Aβ 1–40/42) are cleavage products of the
APP. These form β-sheet rich aggregates and soluble oligomers.
The cleavage products are generated by the proteolytic enzymes
βsecretase and γsecretase. There is also an alternative pathway
where α-secretase cleaves APP. The products of this pathway do
not include Aβ peptides and aggregates do not form (Vassar et al.,
1999). The gene encoding βsecretase 2 is located on chromosome
21, therefore, an extra copy would potentially contribute to the
production of higher levels of toxic Aβ, hence formation of
amyloid plaques early in DS.
However, this extra dosage of APP and BACE may not be
required to produce the AD-like phenotype in DS. This idea
can be derived from observations from an individual who had
an over-expression of APP, but exhibited normal levels of BACE
(Cheon et al., 2008). In a recent study, polymorphisms in BACE2
were shown to be a major factor for the age of onset of AD in the
DS population (Mok et al., 2014) suggesting a significant role for
BACE2 in the development of AD in DS.
In addition, it was shown that the amyloid truncated Aβ
peptides (Aβ 9–42 and Aβ 17–42) form ion channels by
formation of a β-barrel secondary structure (βstrand-turn-
βstrand) that alters calcium (Ca2+) homeostasis providing
additional avenues for the manifestation of AD (Jang et al., 2010).
An alternative mechanism may be that N-terminal truncated
amyloids are neurotoxic because they form fibrils that aggregate
more readily (Pike et al., 1995). These studies suggest that it is not
only Aβ but smaller truncated amyloid peptides which are also
involved in the development of AD.
AD research has focused heavily on APP. However studies
have suggested that APP may not be the only factor involved
in the manifestation of AD. This was demonstrated in mice
where the APP protein was over-expressed in a mouse model
of DS (Ts65Dn). No change in the endosomal phenotype
was observed indicating other factors are necessary for this
alteration (Cataldo et al., 2003). As mentioned above, there are
other genes that could contribute to the development of AD-
like neuropathology that will be discussed later in this review.
Although APP is necessary to develop the disease, it appears
that it alone is not sufficient to cause it. This is why it is
interesting to study DS as it narrows the search done to tri-
somy genes.
Importantly, amyloid plaques are formed as the result of
inappropriate interaction between biometals (iron, copper and
zinc) and beta-amyloid. Indeed, increased levels of zinc promote
Aβ precipitation (Bush et al., 1994). There is also increased levels
of iron in AD patients (Gerlach et al., 1994). These observed
increases in the levels of metals in AD give rise to the questions
of why, how and when these increases occur? This so-called metal
theory of AD and DS will be discussed later in this review.
DOWN SYNDROME CANDIDATE REGION 1
Studies showed that DSCR1 mRNA expression was increased
in post-mortem brains of AD patients compared with aged-
matched non-AD controls (Ermak et al., 2001). DSCR1 is a
regulator of calcineurin and in some cases has been shown to
inhibit calcineurin signaling pathways (Fuentes et al., 2000).
Over-expression of DSCR1 contributes to the formation of neu-
rofibrillary tangles and Aβ deposition (Ermak et al., 2011). As
discussed earlier, formation of neurofibrillary tangles is the first
step of memory loss. Hence, having an extra copy of DSCR1 in
DS could contribute to earlier formation of neurofibrillary tangles
and premature cognitive decline. The formation of tangles could
be facilitated by the enhanced ability of over-activate calcineurin
to dephosphorylate tau but the mechanism has not been fully
elucidated (Ermak et al., 2001; Ma et al., 2004).
INTERSECTIN 1
Another potential gene of interest on chromosome 21 is ITSN1.
This gene appears to be involved in metal homeostasis since
it is involved in receptor mediated endocytosis and one of its
cargos is the transferrin/transferrin receptor complex required for
iron transport into the cell. Transferrin (and its iron cargo) is
transferred from the blood into cells by the formation of a vesi-
cle (clathrin-coated pit) that internalizes the complex. First the
recruitment of adaptor protein complex 2 (AP-2) to the plasma
membrane occurs, and then clathrin is recruited to the cytoplasm
where AP-2 has been recruited. The plasma membrane forms
a vesicle by budding inward. The receptors and bound ligand
(transferrin) are thus taken up by the cell. ITSN1 is involved in
the recruitment of AP-2 and the formation of clathrin-coated pits.
Having an extra copy of the ITSN1 gene in DS could alter receptor
trafficking and consequently iron transport.
METALS
THE METAL THEORY
As discussed above, excess APP and/or its cleavage products is
necessary for the development of AD but, it is not sufficient
to cause it. In addition, clinical trials targeting Aβ (by anti- Aβ
antibodies) have failed to treat AD (Greenberg et al., 2003). Bush
et al. (on the basis of the studies done by them and others) have
proposed that a number of proteins involved in neurodegener-
ation (Aβ, AβPP, tau, presenilin, and β-secretase1) fail in their
ability to regulate metals in the AD brains (Finefrock et al., 2003;
Bonda et al., 2011; Bush, 2013), and consequently these proteins
are overwhelmed by the increased levels of these metals. This leads
to accumulation of extracellular zinc and copper in amyloid, and
an accumulation of intracellular iron in neurons (Bush, 2013).
Iron
Iron is essential for normal neurological function. It is required
for the synthesis of myelin and neurotransmitters (Piñero and
Connor, 2000; Bush, 2013). It is known that free iron accu-
mulates in the brains of AD patients, and that iron transport
and storage are disrupted (Sayre et al., 2000). Another study
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showed that iron stimulates the production of hydroxyl radicals
from hydrogen peroxide, and hence exacerbates oxidative stress.
Iron was increased in all areas of the AD brains compared with
controls and transferrin was increased in the frontal cortex of
AD brains. The transferrin/iron ratio which is indicative of iron
mobilization was reduced in AD brains, indicating a distur-
bance of iron metabolism in the AD population (Loeffler et al.,
1995).
Iron transport into the brain is accomplished by Transferrin
(Tf). Tf is a glycoprotein that carries iron in the blood and regu-
lates iron homeostasis. As mentioned above, ITSN1 is required
for iron internalization. It has been reported that there is an
increase of Tf in brains of DS individuals compared with controls
(Leveugle et al., 1994). An extra copy of ITSN1 could be the
reason for this elevated level of Tf in DS brains, and this level
increases with age in DS. The increased level of Tf is also evident
in the amniotic fluid obtained from women carrying DS foetuses
(Perluigi et al., 2011), suggesting iron-mediated damage starts
during pregnancy.
Ferritin, the iron storage protein is available in the cytosol to
bind the iron that has been endocytosed into the cell. Excess iron
can be transported out of the cell by ferroportin (Fpn). For this to
occur, a ferroxidase enzyme is required. In the glia, ceruloplasmin
is the known ferroxidase (Klomp et al., 1996) but ceruloplasmin is
not produced by neurons. Instead, APP has been implicated in the
process of iron export in neuronal cells. This occurs through the
stabilization of Fpn (Duce et al., 2010). Interestingly, excess dietry
iron fed to APP-knock-out mice induced iron accumulation and
damaged the neocortex (Duce et al., 2010).
Iron regulatory protein (IRP) is a cytoplasmic protein that
regulates iron uptake, storage and usage in response to the con-
centration of cellular iron. The level of iron regulatory protein
(IRP-2) in the whole brain was the same in both AD patients and
controls. However IRP-2 is co-localized to the specific areas with
AD neuropathology (Farrar et al., 1990; Smith et al., 1998), sug-
gesting the regulation of iron uptake, storage and usage changes
in specific parts of AD brains which leads to the development of
the AD neuropathology. The role of IRP-2 and indeed iron in the
patho-biology of AD has been well established, whereas in DS this
needs to be investigated.
Tau protein stabilizes microtubules which are involved in cellu-
lar transport. In AD, excess tau phosphorylation causes formation
of tau clumps (neurofibrillary tangles). This leads to a break
down of nutrient transport and death of the neurons which is
believed to be the first step of memory loss. The appearance
of tau-containing neurofibrillary tangles is one of the later neu-
ropathological hallmarks in AD brains. Tau can bind to iron and
this could contribute to tau aggregation (Adlard and Bush, 2006).
Tau protein is needed for iron-export as it was shown that iron
accumulated in tau-knock-out mice (Lei et al., 2012). Therefore,
excess iron levels in the brain could contribute to memory loss as
the consequence of an increased level of tau aggregation.
Copper
The brain is enriched with copper. Copper has been localized
in mitochondria, synaptosomes and myelin (Nalbandyan, 1983).
In a normal nervous system, copper plays a role in regulating
neuronal excitability (Kardos et al., 1989), myelination, iron
metabolism and the function of copper containing enzymes such
as superoxide dismutase (SOD), dopamine-β monooxygenase
and tyrosinase (Nalbandyan, 1983). As mentioned above, the
SOD1 gene is located on chromosome 21. An extra copy of SOD1
in DS might contribute to a dysfunctional SOD1 enzyme. SOD
is a copper and zinc binding enzyme which is responsible for
destroying free superoxide radicals in the body.
Studies have also shown that APP knockout mice have higher
levels of copper in brain and liver (White et al., 1999) while
the APP-overexpressing transgenic mice have reduced levels
(Maynard et al., 2002) indicating that APP acts as a major regula-
tor of neuronal copper homeostasis. On the other hand, a recent
study showed that copper promotes APP trafficking through
the secretory pathway (Acevedo et al., 2014). Collectively, these
studies suggest there is a two way relationship between copper and
APP.
It is known that copper binding to APP reduces the production
of Aβ in vitro (Barnham et al., 2003). As DS individuals have
an extra copy of the APP gene, it may follow that they would
have reduced levels of copper in their brains and hence increased
production of Aβ leading to the formation of amyloid plaques.
This has yet to be investigated.
It has also been shown that in AD brains, there is an overall
deficiency of copper (Cater et al., 2008) and an increased level
of extracellular copper in amyloid (Bush, 2013) suggesting a
change in the homeostasis of copper in AD. Excess cellular copper
can compromise cell viability by acting as a pro-oxidant and
generating toxic reactive oxygen species via Fenton-type reactions,
involving copper ions and hydrogen peroxide. Therefore, cellular
copper homeostasis must be tightly regulated (Huang et al., 1999)
to maintain healthy brain function.
Zinc
Zinc is essential for the function of numerous enzymes and
transcription factors. In the normal brain, zinc is bound to
membrane-bound metalloproteins, or loosely bound within the
cytoplasm to proteins and enzymes as well as being in synap-
tic vesicles that are enriched with zinc (exceeding 1 mmol/L
in concentration) (Frederickson et al., 2000). During synaptic
transmission, high concentrations of zinc are released into the
synapse from mossy fibers (Sensi et al., 2011). Zinc regulates ion
channels and transmitter receptors such as α-Amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-
aspartate (NMDA) receptors which are implicated in synaptic
plasticity and memory consolidation (Sindreu and Storm, 2011).
Therefore, any change in homeostasis of zinc can have an impact
on learning and memory.
Within the ectodomain 2 (E2) of APP, a metal binding site
has been identified which binds competitively to zinc or copper
(Dahms et al., 2012). Both zinc and copper can interact with Aβ
to form aggregates (Adlard and Bush, 2006). An increase in level
of extracellular zinc in amyloid of AD has been observed (Bush,
2013). Earlier studies demonstrated that a small increase in brain
zinc concentration (>3 micromolar) increased the adhesiveness
of Aβ (Bush et al., 1994) and changed Aβ metabolism. Intrigu-
ingly, the area of the brain with the highest level of zinc, the
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cerebral cortex (Frederickson et al., 1983), exhibits the most severe
pathological lesions of AD (Hyman et al., 1986).
Zinc transporters (ZnT) are also crucial to maintain memory
and cognitive function. There are 10 ZnT known to date. Zinc
uptake into synaptic vesicles needs zinc-transporter-3 (Cole et al.,
1999). It has been demonstrated that zinc-transporter-3 knock-
out mice develop amyloid pathology characteristic of AD (Adlard
et al., 2010) supporting a role for the zinc transporter in the man-
ifestation of AD. Another study showed that zinc-transporter-
6, which is located in the Golgi apparatus, is involved in the
accumulation of zinc (Lyubartseva et al., 2010). The role of ZnT
is yet to be investigated in DS.
Calcium (Ca2+)
Calcium plays an important role in the central nervous system. It
acts as a cofactor, second messenger and signaling molecule, and
a coenzyme when part of a protein. It is also part of excitatory
function of neuronal cells, being involved in voltage-gated cal-
cium ion channels. It has been shown that voltage-gated calcium
ion channel activity in a mouse model of DS (trisomy 16 mouse;
Ts16) was significantly higher than the wild type (Galdzicki et al.,
1998). This increased activity could potentially lead to altering
calcium homeostasis in the brains of DS individuals.
Human chromosome 21 has two genes of interest that modu-
late calcium; the S100β gene stimulates calcium influx (Mattson
et al., 1993a,b) and the DSCR1 gene, which is a regulator of
calcineurin and in some circumstances, can inhibit calcineurin
signaling pathways. It has been shown that calcineurin regu-
lates Ca2+ pumps and exchangers to maintain Ca2+ homeostasis
(Stark, 1996). Having an extra copy of DSCR1 could potentially
change calcium homeostasis in the brains of people with DS by
influencing the activity of calcineurin, leading to formation of
neurofibrillary tangles and consequently memory loss.
In AD, Aβ binds to neurons in close proximity to the NMDA-
R which triggers NMDA-R- mediated calcium influx and alters
calcium homeostasis (De Felice et al., 2007). Another report
suggesting altered calcium homeostasis contributed to AD came
from a study on L-type voltage gated calcium channels (LTVGCC)
(Anekonda et al., 2011). In this study MC65 neuroblastoma
cells were exogenously transfected with APP under the control
of a tetracycline-responsive promoter. Upon the withdrawal of
tetracycline, production of APP and Aβ fragments was observed
along with up-regulation of LTVGCC, leading to increased cal-
cium influx (Anekonda et al., 2011). Interestingly the use of
calcium channel blockers prevented the neurotoxicity of Aβ. It
has been suggested that the neurotoxicity of Aβ is due to the
presence of elevated calcium ions, resulting in increased responses
to excitatory amino acids such as glutamate (Mattson et al.,
1993a). Due to these increased responses, glutamate receptors
are over activated which result in dendritic pruning, increased
immunoreactivity of tau, and an accumulation of filaments. These
are all characteristics of neurofibrillary tangles of AD in DS and
non-DS individuals.
CONCLUSION
An extra dosage of the genes on chromosome 21 could contribute
directly or indirectly (by changing metal homeostasis) to the
manifestation of AD-like neuropathology in DS. There might be
more genes involved in these processes other than the ones dis-
cussed in this review. Although some studies have been conducted
on cognitive decline in DS individuals, the molecular mechanisms
involved in this cognitive decline remain unknown. More studies
are required to investigate these mechanisms and thus provide
avenues to explore for the prevention of the cognitive decline
characteristic of AD in DS and in the non-DS population.
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